Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
Blood|January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemiaStephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung CancerSolange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2025
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER StudyAntonio Calles, Alejandro Navarro, Bernard Gaston Doger de Speville Uribe, et al.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Nature Medicine|February 6, 2024
MYC targeting by OMO-103 in solid tumors: a phase 1 trialElena Garralda, Marie-Eve Beaulieu, Víctor Moreno, et al.
Science Translational Medicine|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumorsIgnacio Melero, Tamara Tanos, Mariana Bustamante, et al.
Pageof 18